相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Targeting autophagy-related protein kinases for potential therapeutic purpose
Honggang Xiang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Discovery of Nonpeptide, Environmentally Sensitive Fluorescent Probes for Imaging p53-MDM2 Interactions in Living Cell Lines and Tissue Slice
Gaopan Dong et al.
ANALYTICAL CHEMISTRY (2020)
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Yuan Fang et al.
ACTA PHARMACEUTICA SINICA B (2020)
PROTAC Technology: Opportunities and Challenges
Hongying Gao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
Hongying Gao et al.
PROTEIN & CELL (2020)
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects
Yiqing Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Taavi Neklesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Stefanie Lindner et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2019)
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Development of selective small molecule MDM2 degraders based on nutlin
Bo Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders
Jiuling Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeted protein degradation: expanding the toolbox
Matthieu Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
John Hines et al.
CANCER RESEARCH (2019)
Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors
Ryan P. Wurz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
Yangbing Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
PROTAC-mediated crosstalk between E3 ligases
Christian Steinebach et al.
CHEMICAL COMMUNICATIONS (2019)
Inducing Protein Degradation as a Therapeutic Strategy
Craig M. Crews
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a
Lei Duan et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2018)
Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders
Mette Ishoey et al.
ACS CHEMICAL BIOLOGY (2018)
Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis
Mikhail M. Savitski et al.
CELL (2018)
The dTAG system for immediate and target-specific protein degradation
Behnam Nabet et al.
NATURE CHEMICAL BIOLOGY (2018)
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
Shipeng He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Ubiquitin ligases in oncogenic transformation and cancer therapy
Daniela Senft et al.
NATURE REVIEWS CANCER (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Andrew J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
Chiara Maniaci et al.
NATURE COMMUNICATIONS (2017)
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors
Shengzheng Wang et al.
ORGANIC LETTERS (2016)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Camelia Iancu-Rubin et al.
EXPERIMENTAL HEMATOLOGY (2014)
Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53-MDM2 Interaction and the NF-κB Pathway
Chunlin Zhuang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53-MDM2 Protein-Protein Interaction
Chunlin Zhuang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Targeting IAP proteins for therapeutic intervention in cancer
Simone Fulda et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
The Regulation of the p53-mediated Stress Response by MDM2 and MDM4
Mary Ellen Perry
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces
James A. Wells et al.
NATURE (2007)
Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
MR Arkin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
MDM2 - master regulator of the p53 tumor suppressor protein
J Momand et al.
GENE (2000)
分享论文
